# üíÄ GSE206422 DATA VERIFICATION REPORT

**Date:** January 25, 2026  
**Dataset:** GSE206422 (Ovarian IO Trial NCT02853318)  
**Status:** ‚ö†Ô∏è **PARTIAL - RESPONSE DATA MISSING FROM GEO**

---

## ‚úÖ WHAT WE HAVE:

| Component | Status | Details |
|-----------|--------|---------|
| **RNA-seq counts** | ‚úÖ Available | 58,037 genes √ó 73 samples |
| **TIL genes** | ‚úÖ 13/13 (100%) | CD8A, CD8B, CD3D, CD3E, CD3G, CD4, CD2, GZMA, GZMB, PRF1, IFNG, TNF, IL2 |
| **Exhaustion genes** | ‚úÖ 7/8 (88%) | PDCD1, CTLA4, LAG3, TIGIT, HAVCR2, BTLA, CD96 *(VSIR missing)* |
| **Unique patients** | ‚úÖ ~40 | Based on sample naming |
| **Sample types** | ‚úÖ Longitudinal | BLBX (baseline), C4BX (cycle 4), EOTBX (end of treatment), Primary |

---

## ‚ùå WHAT'S MISSING:

| Component | Status | Details |
|-----------|--------|---------|
| **Response labels** | ‚ùå NOT IN GEO | Not in sample metadata |
| **Patient-level clinical data** | ‚ùå NOT IN GEO | Not in series metadata |
| **RECIST response** | ‚ùå NEED SUPPLEMENTARY | In publication (Nat Commun Dec 2024) |

---

## üìä KNOWN RESPONSE DATA (FROM PUBLICATION):

| Response | Count | % |
|----------|-------|---|
| Complete Response (CR) | 3 | 7.5% |
| Partial Response (PR) | 16 | 40.0% |
| Stable Disease (SD) | 19 | 47.5% |
| Progressive Disease (PD) | 2 | 5.0% |
| **Objective Response Rate (ORR)** | 19 | **47.5%** |
| **n (total)** | 40 | |

---

## üéØ ACTION REQUIRED:

### Option 1: Extract from Publication Supplementary

**Publication:** Nature Communications, Dec 2024, PMID 39638782

**Supplementary Files to Check:**
- Source Data 1 (Excel) - may contain patient-level response
- Supplementary Tables

**Task for Agent X:**
> Scrape Nature Communications supplementary data for PMID 39638782.
> Look for: Patient-level table with response (CR/PR/SD/PD) linked to sample IDs.
> Required mapping: Sample ID (e.g., "1-BLBX") ‚Üí Response category

### Option 2: Use Durable Response Definition

The paper mentions "exceptional clinical responses" and "durable response" (>12 months).

If we can identify which patient IDs had durable vs non-durable response:
- Durable response = Responder
- Short response = Non-responder

This may be in Figure 1 or supplementary tables.

### Option 3: Contact Authors

Authors at Roswell Park Comprehensive Cancer Center.
Request: Patient-level response data for GSE206422 samples.

---

## üìã SAMPLES BREAKDOWN:

| Sample Type | Count | Description |
|-------------|-------|-------------|
| **BLBX** | ~40 | Baseline biopsy (PRE-TREATMENT) ‚úÖ |
| C4BX | ~25 | Cycle 4 biopsy (ON-TREATMENT) |
| EOTBX | ~5 | End of treatment biopsy |
| Primary | ~5 | Primary tumor |

**For IO prediction, we need BLBX (baseline) samples with matched response.**

---

## üíÄ VERDICT:

| Criterion | Status | Impact |
|-----------|--------|--------|
| Gene coverage | ‚úÖ PASS | 96% coverage |
| Sample size | ‚úÖ PASS | ~40 patients |
| Pre-treatment samples | ‚úÖ PASS | BLBX available |
| Response labels | ‚ùå **FAIL** | **BLOCKING** |

**Cannot proceed with validation until response labels obtained.**

---

## üìã NEXT STEPS:

| Priority | Action | Owner | Timeline |
|----------|--------|-------|----------|
| **P0** | Download Nat Commun supplementary data | Agent X | ASAP |
| **P0** | Look for patient-response mapping | Zo | After data received |
| **P1** | Check alternative datasets if blocked | Zo | 24h |

---

## Alternative Datasets to Check:

| GEO ID | Cancer | Treatment | Status |
|--------|--------|-----------|--------|
| GSE271757 | Ovarian | Pembro + Chemo | ‚è≥ Not verified |
| GSE227666 | Ovarian | NACT ¬± Pembro | ‚è≥ Not verified |
| GSE179994 | NSCLC | Pembrolizumab | ‚è≥ Not verified |
